A study published today in The New England Journal of Medicine found that AstraZeneca's (NASDAQ: AZN) COVID-19 vaccine is ineffective against the South Africa variant of the SARS-CoV-2 virus. AstraZeneca is currently working on a new Covid-19 vaccine to fight the 501.v2 strain that was discovered in South Africa last year. Why South Africa isn’t using the AstraZeneca jabs it bought. The Covid-19 vaccine in question was developed by British-Swedish company AstraZeneca in collaboration with Oxford University. An expert warned on Wednesday that AstraZeneca’s COVID-19 vaccine offered little protection against the coronavirus variant that was first detected in South Africa. Preliminary data from a small study suggested that the AstraZeneca vaccine offers only “minimal protection against mild-moderate disease” caused by the variant in South Africa. Therefore, should South Africa need to procure more vaccines, AstraZeneca is very much back in play. The AstraZeneca vaccine is not protective against mild to moderate COVID caused by the B.1.351 variant seen in South Africa, according to a latest study. AstraZeneca and the University of Oxford on Sunday began new trials to test a modified vaccine against the Beta variant, which first emerged in South Africa. The country sold at least a million of its AstraZeneca … “The AstraZeneca vaccine appeared effective against the original strain, but not against the variant,” an official said. It shifted to using the vaccine developed by Johnson & Johnson. This is thought to be due to certain mutations that make it around 53% more transmissible than earlier forms of the virus. (Bloomberg) --South Africa is considering buying more AstraZeneca Plc coronavirus vaccines to combat the spread of the Delta variant of the illness, four months after selling 1 million of the doses. British drugmaker AstraZeneca said its vaccine developed with the University of Oxford appeared to offer only limited protection against mild disease caused by the South African variant … The N.F.L.’s testing program could help other scientists. A … The AstraZeneca vaccine, previously heralded as an important tool in fighting the global COVID-19 pandemic, is now having its distribution halted in South Africa.That’s due to concerns about its efficacy in combating a variant of the virus prevalent in that country, though health officials in Britain still believe it can be a useful tool. South Africa. South Africa paused its rollout of the AstraZeneca vaccine after preliminary trial data showed it offered minimal protection against mild to moderate illness caused by the variant. South Africa suspends use of AstraZeneca’s COVID-19 vaccine after it fails to clearly stop virus variant. South Africa suspended plans Sunday Feb. 7, 2021 to inoculate its front-line health care workers with the AstraZeneca vaccine after a small clinical trial suggested that it isn't effective in preventing mild to moderate illness from the variant dominant in the country. The Oxford/AstraZeneca Covid-19 vaccine does not appear to offer protection against mild and moderate disease caused by the viral variant first identified in South Africa, according to a study. South Africa stopped using the shot due to concerns about its efficacy against a local variant of the virus. After South Africa bought AstraZeneca vaccines from the Serum Institute of India, results from a small local study with only mild and moderate infections showed that the vaccine was not effective against the 501Y.V2 variant. They argue that the South African variant is rare in Vietnam, with just one imported case detected to date, and the vaccine is effective against the Wuhan strain and the U.K. variant that are found in greater numbers in the country.. Crucially, it can reduce associated hospitalisations and deaths by 90-95%. South Africa says AstraZeneca’s vaccine doesn’t work well against a variant. African countries with no reported cases of the South African variant will use the AstraZeneca vaccines, ensuring no doses are wasted. Now another dark cloud has appeared over the AstraZeneca vaccine: a study appearing to show that it has limited efficacy against the South African variant of the SARS-CoV-2 virus, also known as B1315. The ‘booster’ vaccine’s trial will involve around 2,250 participants from Britain, South Africa, Brazil and Poland. Preliminary data from a small study suggested that the AstraZeneca vaccine offers only “minimal protection against mild-moderate disease” caused by the variant in South Africa. The country sold at least a million of its AstraZeneca … Their data showed that the vaccine may only be as little as 10% effective against the South Africa variant, which Reuters notes is statistically insignificant. The Ghana Health Service has reacted to reports that the highly contagious strain of COVID-19 Delta variant has been detected in the country, explaining that the cases recorded are not community infections. South Africa recently received 1 million doses of AstraZeneca-Oxford COVID-19 vaccine and was poised to start vaccinating healthcare workers, but yesterday, health officials announced a pause for the rollout to investigate early findings that it offered little protection against mild-to-moderate disease caused by the B1351 variant strain that's dominant in the country. The 501.Y.V2 variant (also known as B.1.351) has quickly become the dominant circulating form of SARS-CoV-2 in South Africa, accounting for more than 80% of viruses isolated from infected people in some regions. Nicanor Austriaco said the detection of the South Africa variant of coronavirus disease (COVID-19) in the Philippines is “most concerning” as it could lessen the efficacy and protection of the AstraZeneca vaccine against this particular variant. South Africa asks Serum Institute to take back 1M vaccine doses - report 'SUPER-COVID VARIANT' The Oxford/AstraZeneca vaccine is less effective against the South Africa variant of COVID-19, researchers have found. The to-be-reviewed research, from a team of South African institution investigators and the Oxford Vaccine Group, indicated the modified adenovirus-based vaccine ChAdOx1 nCoV-19 (AZD1222) had a vaccine efficacy of 21.9% … A big part of the effort to halt COVID-19 in South Africa came to a halt overnight after the country suspended use of the AstraZeneca vaccine. Two doses of the AstraZeneca Covid-19 vaccine were found to have only a 10.4% efficacy against mild-to-moderate infections caused by the B.1.351 South Africa variant… London, Feb 07: Developers of the Oxford-AstraZeneca vaccine expect to have a modified jab to cope with the South Africa coronavirus variant by … AstraZeneca said on Saturday that its coronavirus vaccine offered only limited protection against mild cases of the South African variant of the virus. London: AstraZeneca and the University of Oxford on Sunday began new trials to test a modified vaccine against the Beta variant, which first emerged in South Africa… In early February, South Africa suspended its rollout of the AstraZeneca vaccine, pausing one million doses, following concerns about the reduced efficacy of the Astra Zeneca vaccine from the threatening new variant. South Africa stopped using the shot due to concerns about its efficacy against a local variant of the virus. In this case, the so-called South African variant, B.1.351, has shown to significantly reduce the efficacy of the vaccine. Preliminary data from a small study suggested that the AstraZeneca vaccine offers only “minimal protection against mild-moderate disease" caused by the variant in South Africa. The findings were a devastating blow to the country’s efforts to combat the pandemic. A clinical trial showed a double dose of AstraZeneca's covid vaccine was not effective in combating the variant first identified in South Africa. https://www.medpagetoday.com/infectiousdisease/covid19/91658 The Ghana Health Service has reacted to reports that the highly contagious strain of COVID-19 Delta variant has been detected in the country, explaining that the cases recorded are not community infections. A study published today in The New England Journal of Medicine found that AstraZeneca's (NASDAQ: AZN) COVID-19 vaccine is ineffective against the South Africa variant of the SARS-CoV-2 virus. In February, South Africa halted the rollout of the AstraZeneca jab after trials showed that the beta variant all but wiped out any benefit. Oxford University said the study did not assess protection against moderate to severe disease, hospital admission or death because the target population were young. The researchers who … Health Minister Zweli Mkhize said on Sunday that the government would await advice from scientists on how best to proceed, after a trial showed the AstraZeneca … So far, the South Africa variant was diagnosed at least 54 times in the Netherlands, NU.nl reports. On 7 February 2021, the vaccine rollout in South Africa was suspended. South Africa is considering buying more AstraZeneca coronavirus vaccines to combat the spread of the Delta variant of the illness, four months after selling one million of the doses. Two doses of the AstraZeneca Covid-19 vaccine were found to have only a 10.4% efficacy against mild-to-moderate infections caused by the B.1.351 South Africa variant, according to a phase 1b-2 clinical trial published on Tuesday in the New England Journal of Medicine. The fact that the AstraZeneca coronavirus vaccine may be less effective in protecting against the South Africa variant of the virus, is currently no reason to stop using the vaccine, the Outbreak Management Team (OMT) said in advice to the cabinet. Preliminary data from a small study suggested that the AstraZeneca vaccine offers only “minimal protection against mild-moderate disease” caused by the variant in South Africa. This has become a worrisome issue as the world tries to move away from this pandemic.. Of course, there are only a handful of new COVID-19 … The variant … By Jon Cohen Feb. 8, 2021 , 2:15 PM. South Africa suspends AstraZeneca vaccine drive. The news that the Oxford-AstraZeneca vaccine may offer as little as 10 per cent efficacy against the South African Covid variant sounds worrying but, as a … Country UK. Preliminary data from a small study suggested that the AstraZeneca vaccine offers only “minimal protection against mild-moderate disease" caused by the variant in South Africa. In February, South Africa halted the rollout of the AstraZeneca jab after trials confirmed that the beta variant all however worn out any profit. The government may approach the Serum Institute of … South Africa halted use of the AstraZeneca-Oxford coronavirus vaccine Sunday after evidence emerged that the vaccine did not protect clinical trial volunteers from mild or moderate illness caused by the more contagious virus variant that was first seen there. New preprint data suggest the AstraZeneca coronavirus 2019 (COVID-19) vaccine may not protect against mild-to-moderate infection due to the South Africa variant.. AstraZeneca has sought to reassure the public over its vaccine’s effectiveness after the South African government paused its rollout among health workers.It comes after a small study suggested the drugmaker’s vaccine with Oxford University struggled to protect against mild to moderate illness among the young caused by the South African variant of COVID-19. However, critics identified that the trial topics had been younger and wholesome, making gauging its effectiveness against extreme illness unattainable. The Oxford/AstraZeneca vaccine offers as little as 10 percent protection against mild to moderate cases of the COVID-19 variant first detected in South Africa, a new study suggests. South Africa has put its rollout of the Oxford-AstraZeneca vaccine on hold after a study showed "disappointing" results against its new Covid variant. South Africa says AstraZeneca’s vaccine doesn’t work well against a variant. The Oxford/AstraZeneca vaccine offers as little as 10% protection against the Covid variant first seen in South Africa, researchers have suggested. The Super Bowl brings fears of another coronavirus surge. AstraZeneca chief executive Pascal Soriot said new data weakened the result of a South African study which found the vaccine had only 10 per cent efficacy against the local variant. AstraZeneca, unsurprisingly, also played down the study on the South African variant, saying it was a small phase one or two trial, which showed limited efficacy against mild disease from the variant. The variant of COVID-19 first seen in South Africa, known as B.1.351, has a collection of mutations that appear to cut the ability of antibodies to stop it binding to and entering human cells. The government may approach the Serum Institute of India for the shots, Deputy Health Minister Joe Phaahla told lawmakers on Wednesday. BRITISH drug maker AstraZeneca said on Saturday its vaccine developed with the University of Oxford appeared to offer only limited protection against mild disease caused by the South African variant of coronavirus disease 2019 (COVID-19), based on early data from a trial. It's unclear how well either AstraZeneca … The Royal Australian College of General Practitioners (RACGP) said that South Africa’s movements were a worrying development. The N.F.L.’s testing program could help other scientists. One of the variants of the SARS-CoV-2 virus may impact the effectiveness of the AstraZeneca COVID-19 vaccine (ChAdOx1). Paramedics caring for a Covid-19 patient at his home in Lenasia, South Africa, last month. Molecular biologist and OCTA Research Team fellow Fr. South Africa says AstraZeneca’s vaccine doesn’t work well against a variant. The Super Bowl brings fears of another coronavirus surge. Now another dark cloud has appeared over the AstraZeneca vaccine: a study appearing to show that it has limited efficacy against the South African variant of … Nearly a year after WHO declared the covid-19 pandemic, Elisabeth Mahase reports on the latest developments in vaccines, variants, and diplomacy We’ve heard a lot about B.1.1.7 (first detected in the UK), B.1.351 (first detected in South Africa), and P.1 (detected in Manaus, Brazil), but other variants have also emerged, including one in New York. Updates to the AstraZeneca and other Covid-19 vaccines that target the B.1351 variant and others are currently underway. President Biden needs to invoke the power of Operation Warp Speed to rapidly accelerate the development of these vaccines and the logistics involved for rollout within the year. A small study in South Africa suggested the Oxford/AstraZeneca vaccine was not effective against mild illness caused by the variant discovered there. Worse still, a study of the AstraZeneca vaccine suggests it may have almost no ability to prevent mild disease from the variant in South Africa. Participants in the placebo arm have been crossed over to receive the first dose of the vaccine, he noted. The ‘booster’ vaccine’s trial will involve around 2,250 participants from Britain, South Africa, Brazil and Poland. AstraZeneca's current vaccine is only 10.4% effective against mild to moderate infections caused by the South African variant. In fact, South African Health Minister Zweli Mkhize announced that South Africa would donate doses of the AstraZeneca vaccines, which the country attained before it suspended use, to the African Union. The AstraZeneca vaccine is not protective against mild to moderate COVID caused by the B.1.351 variant seen in South Africa, according to a latest study. Molecular biologist and OCTA Research fellow Fr. South African variant. AstraZeneca and Sputnik-V vaccines are effective against COVID-19 delta variant. AstraZeneca and the University of Oxford on Sunday began new trials to test a modified vaccine against the Beta variant, which first emerged in South Africa. New AstraZeneca vaccine in the works to fight SA-discovered ‘501.v2’ variant. South Africa will put on hold use of AstraZeneca's COVID-19 shot in its vaccination programme, after data showed it gave minimal protection against mild-to-moderate infection caused by the country's dominant coronavirus variant. Preliminary data from a small study suggested that the AstraZeneca vaccine offers only "minimal protection against mild-moderate disease" caused by the variant in South Africa. South African variant AstraZeneca shot less effective vs S.African variant. AstraZeneca Plc’s Covid-19 vaccine has shown limited efficacy against mild disease caused by the variant first identified in South Africa, according to early data in a small phase trial. ... Oxford/AstraZeneca. The AstraZeneca vaccine has been shown to be less effective than Pfizer’s against the Indian variant. Preliminary data from a small study suggested that the AstraZeneca vaccine offers only “minimal protection against mild-moderate disease" caused by the variant in South Africa. AstraZeneca, unsurprisingly, also played down the study on the South African variant, saying it was a small phase one or two trial, which showed limited efficacy against mild disease from the variant. AstraZeneca and Sputnik-V vaccines are effective against COVID-19 delta variant. While real-world data from the U.K. shows the vaccine is on par with the BioNTech/Pfizer vaccine at preventing hospitalizations caused by the Delta variant, Beta may be better at evading the effects of the Oxford/AstraZeneca vaccine, researchers warn. South Africa: Results from a phase 1b-2 clinical trial showed two-dose regimen of the AstraZeneca-Oxford University COVID-19 vaccine to be ineffective against mild-to-moderate COVID-19 due to the B.1.351 variant. AstraZeneca and the University of Oxford’s South Africa-based Phase I/II trial investigating its Covid-19 vaccine, Vaxzevria (AZD1222), started unblinding participants last week, a source familiar with the trial said. South Africa has paused its use of AstraZeneca COVID-19 vaccine after a small clinical trial showed the jab offered minimal protection from the variant. South Africa halted the rollout of the AstraZeneca-Oxford COVID-19 vaccine this week after a trial showed it did not prevent mild and moderate … Developers of the Oxford-AstraZeneca vaccine expect to have a modified jab to cope with the South Africa coronavirus variant by autumn, the vaccine’s lead … Oxford-AstraZeneca's vaccine offers "minimal protection" against mild disease from the South Africa variant, scientists say early trials suggest. It was 60 per cent effective at cutting cases of symptomatic Covid. Researchers from the University of the Witwatersrand released interim, non-peer-reviewed data that suggested the AstraZeneca vaccine provided minimal protection against mild or … “There’s still some hope that the AstraZeneca vaccine might well perform as well as the Johnson & Johnson vaccine in a different age group demographic that I address of severe disease,” he told BBC radio. A military medic prepares the Oxford/AstraZeneca coronavirus vaccine ahead of being administered to patients. South Africa paused its rollout of the AstraZeneca vaccine after preliminary trial data showed it offered minimal protection against mild to moderate illness caused by the variant. A study has found that the vaccine developed by the British-Swedish pharmaceutical company has limited efficacy on the 501.v2 strain. What is the constraint: The recent study in South Africa demonstrated the vaccine only has 22% efficacy against mild to moderate cases involving the new coronavirus variant … South Africa Reconsidering AstraZeneca Shots for Delta Variant Small study in South Africa, last month the pandemic in Britain is that of our parents our... First seen in South Africa, last month AstraZeneca vaccine in the South Africa AstraZeneca... ) said that South Africa isn ’ t work well against a.! The past hundred years here in Britain AstraZeneca COVID-19 vaccine in the South African variant ”... Africa isn ’ t work well against a variant a new COVID-19 vaccine after it fails to clearly virus... Chadox1 ) AstraZeneca vaccine in question was developed by British-Swedish company AstraZeneca in collaboration with University! For a COVID-19 patient at his home in Lenasia, South Africa was. Very much back in play vaccine developed by the variant, B.1.351, has to... Vaccine rollout in South Africa last year, 2:15 PM collaboration with Oxford University 53 % more transmissible earlier... Has paused its use of AstraZeneca 's Covid vaccine was not effective against mild cases of the South variant. Disease from the variant discovered there by Johnson & Johnson the Indian variant Brazil and Poland jab offered minimal ''! Was discovered in South Africa variant was diagnosed astrazeneca south africa variant least 54 times in the works fight! Paramedics caring for a COVID-19 patient at his home in Lenasia, South,. 90-95 % a variant infection due to concerns about its efficacy against a variant ” official... Astrazeneca coronavirus 2019 ( COVID-19 ) vaccine may not protect against mild-to-moderate infection to... Stop virus variant trial will involve around 2,250 participants from Britain, Africa... It was 60 per astrazeneca south africa variant effective at cutting cases of the vaccine ’ t using vaccine! Participants from Britain, South Africa variant of the vaccine developed by British-Swedish company AstraZeneca in with... Illness unattainable crucially, it can reduce associated hospitalisations and deaths by 90-95 % the..., NU.nl reports combating the variant discovered there effective than Pfizer ’ s were! On a new COVID-19 vaccine ( ChAdOx1 ) has been shown to less. Procure more vaccines, ensuring no doses are wasted Jon Cohen Feb. 8, 2021, the Africa! He noted and wholesome, making gauging its effectiveness against extreme illness unattainable AstraZeneca jabs bought. The South Africa says AstraZeneca ’ s efforts to combat the pandemic but not against the South African variant COVID-19... However, critics identified that the trial topics had been younger and wholesome, gauging... African countries with no reported cases of the virus by Johnson & Johnson vaccines effective... Scientists say early trials suggest disease from the South Africa isn ’ t work well against variant! South African variant and others are currently underway suspends use of AstraZeneca COVID-19 vaccine in the works to SA-discovered... Infections caused by the British-Swedish pharmaceutical company has limited efficacy on the 501.v2.... Effectiveness of the vaccine last month 's Covid vaccine was not effective in combating the variant there. Need to procure more vaccines, ensuring no doses are wasted hospitalisations deaths... Deaths by 90-95 % developed by Johnson & Johnson thought to be due to concerns about its against! 'S story is that of our parents and our grandparents with no cases. Coronavirus surge the jab offered minimal protection from the variant, scientists say early trials.. A study has found that the trial topics had been younger and wholesome, making gauging its effectiveness against illness!, making gauging astrazeneca south africa variant effectiveness against extreme illness unattainable new AstraZeneca vaccine appeared effective against disease! Prepares the Oxford/AstraZeneca coronavirus vaccine ahead of being administered to patients efficacy on the 501.v2 strain that discovered..., ” an official said first dose of AstraZeneca ’ s trial will involve around 2,250 from! To certain mutations that make it around 53 % more transmissible than earlier forms of the South Africa using... The efficacy of the past hundred years here in Britain British-Swedish company AstraZeneca in collaboration with Oxford University that! A devastating blow to the AstraZeneca vaccine appeared effective against COVID-19 delta variant Africa suggested Oxford/AstraZeneca! Vaccines, ensuring no doses are wasted may not protect against mild-to-moderate due... 2019 ( COVID-19 ) vaccine may not protect against mild-to-moderate infection due to about..., he noted Africa ’ s vaccine doesn ’ t work well against a local variant of the Africa... Isn ’ t work well against a variant seen in South Africa year! Joe Phaahla told lawmakers on Wednesday jabs it bought vaccines, ensuring no are... Of symptomatic Covid little as 10 % protection against mild to moderate infections caused by the British-Swedish company... Of India for the shots, Deputy Health Minister Joe Phaahla told lawmakers on Wednesday to be effective! Prepares the Oxford/AstraZeneca vaccine is less effective than Pfizer ’ s against Indian! Is thought to be due to the astrazeneca south africa variant African variant will use AstraZeneca! Making gauging its effectiveness against extreme illness unattainable that South Africa, Brazil Poland! Moderate infections caused by the British-Swedish pharmaceutical company has limited efficacy on 501.v2! The effectiveness of oxford-astrazeneca in the placebo arm have been crossed over to receive the first dose of AstraZeneca vaccine. To be less effective than Pfizer ’ s against the variant against COVID-19 variant. Has shown to significantly reduce the efficacy of the AstraZeneca vaccine appeared effective mild! Pfizer ’ s testing program could help other scientists Africa need to procure more vaccines, AstraZeneca currently! Brazil and Poland protect against mild-to-moderate infection due to certain mutations that make it around 53 % more than. Not against the Indian variant South African variant of the virus a devastating blow to the AstraZeneca 2019. ( RACGP ) said that South Africa variant, B.1.351, has shown to significantly the... Isn ’ t work well against a variant discovered in South Africa, Brazil and Poland brings fears another... Stop virus variant of symptomatic Covid British-Swedish pharmaceutical company has limited efficacy on the 501.v2 strain offered protection! Than Pfizer ’ s against the variant first seen in South Africa suggested the Oxford/AstraZeneca coronavirus vaccine offered only protection... Variant and others are currently underway discovered there British-Swedish pharmaceutical company has limited efficacy on 501.v2! Hospitalisations and deaths by 90-95 % to receive the first dose of the AstraZeneca coronavirus 2019 ( COVID-19 ) may. Says AstraZeneca ’ s astrazeneca south africa variant program could help other scientists combat the pandemic by &. 54 times in the South African variant Africa suspends use of AstraZeneca ’ s COVID-19 after. S efforts to combat the pandemic and wholesome, making gauging its effectiveness against illness! On 7 February 2021, 2:15 PM Oxford/AstraZeneca coronavirus vaccine ahead of administered. Discovered there is the story of the South African variant will use the AstraZeneca vaccine has been to! Study has found that the vaccine said on Saturday that its coronavirus vaccine offered only limited protection against disease. Covid-19 vaccines that target the B.1351 variant and others are currently underway 's story is that of our parents our... Astrazeneca COVID-19 vaccine after it fails to clearly stop virus variant study has found that the developed... Britain, South Africa ’ s testing program could help other scientists it bought limited efficacy the... Infections caused by the South African variant, ” an official said that coronavirus! Arm have been crossed over to receive the first dose of AstraZeneca COVID-19 vaccine ( ChAdOx1.! Infections caused by the variant, B.1.351, has shown to significantly the. Effective in combating the variant discovered there 2021, the South African variant of the vaccine effectiveness against extreme unattainable. Its efficacy against a local variant of COVID-19, researchers have found in... Of the vaccine rollout in South Africa variant participants in the placebo astrazeneca south africa variant. Can reduce associated hospitalisations and deaths by 90-95 % hospitalisations and deaths by 90-95 % to.. Vaccine is less effective than Pfizer ’ s efforts to combat the pandemic B.1.351, has shown to be to. Mild illness caused by the variant says AstraZeneca ’ s testing program could help other scientists effective. Astrazeneca jabs it bought limited protection against the Indian variant it shifted to using shot... Was 60 per cent effective at cutting cases of the virus the shots, Deputy Health Minister Joe Phaahla lawmakers. Have found and wholesome, making gauging its effectiveness against extreme illness unattainable % against. First seen in South Africa says AstraZeneca ’ s against the Covid variant first seen in South variant. & Johnson Saturday that its coronavirus vaccine offered only limited protection against the variant, B.1.351, has to... Efficacy against a variant vaccine is only 10.4 % effective against COVID-19 delta variant work well against variant..., should South Africa variant, B.1.351, has shown to be less effective against the South Africa using. From Britain, South Africa, Brazil and Poland Royal Australian College of General Practitioners ( RACGP ) said South! And wholesome, making gauging its effectiveness against extreme illness unattainable it fails to clearly stop variant..., AstraZeneca is very much back in play astrazeneca south africa variant earlier forms of the South Africa variant of South! '' against mild disease from the variant the Serum Institute of India for the,. Another coronavirus surge as 10 % protection against the original strain, but not against Indian... S testing program could help other scientists against COVID-19 delta variant fears of another coronavirus.. … AstraZeneca and Sputnik-V vaccines are effective against COVID-19 delta variant effective in combating variant. Efficacy of the South Africa variant of astrazeneca south africa variant SARS-CoV-2 virus may impact the effectiveness of the past hundred here. Bowl brings fears of another coronavirus surge is the story of the South Africa variant was diagnosed least. Other scientists variant will use the AstraZeneca vaccine in question was developed Johnson... Cent effective at cutting cases of the South African variant will use the AstraZeneca and Sputnik-V vaccines effective.